, healthcare providers are encouraged to report the adverse effect to the FDA.
ADVERSE REACTIONS
Severe
hyperkalemia / Delayed / 12.0-12.0
renal failure (unspecified) / Delayed / 5.0-5.0
angioedema / Rapid / 0.5-0.5
laryngeal edema / Rapid / Incidence not known
teratogenesis / Delayed / Incidence not known
oliguria / Early / Incidence not known
azotemia / Delayed / Incidence not known
Moderate
hypotension / Rapid / 18.0-18.0
orthostatic hypotension / Delayed / 2.1-2.
Mild
cough / Delayed / 9.0-9.0
dizziness / Early / 6.0-6.0
DRUG INTERACTIONS
Acarbose: Angiotensin II receptor antagonists (ARBs) may enhance the hypoglycemic effects of antidiabetic agents by improving insulin sensitivity. In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in the development of new-onset diabetes in patients with hypertension or other cardiac disease. Patients receiving an ARB in combination with antidiabetic agents should be monitored for changes in glycemic control.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists. Well-controlled hypertensive patients receiving pseudoephedrine at recommended doses do not appear at high risk for significant elevations in blood pressure, however, increased blood pressure (especially systolic hypertension) has been reported in some patients.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists.
Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists. Well-controlled hypertensive patients receiving pseudoephedrine at recommended doses do not appear at high risk for significant elevations in blood pressure, however, increased blood pressure (especially systolic hypertension) has been reported in some patients.
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists. Well-controlled hypertensive patients receiving pseudoephedrine at recommended doses do not appear at high risk for significant elevations in blood pressure, however, increased blood pressure (especially systolic hypertension) has been reported in some patients.
Acetaminophen; Dextromethorphan; Phenylephrine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists. Well-controlled hypertensive patients receiving pseudoephedrine at recommended doses do not appear at high risk for significant elevations in blood pressure, however, increased blood pressure (especially systolic hypertension) has been reported in some patients.
Acetaminophen; Dextromethorphan; Pseudoephedrine: The cardiovascular effects of sympathomimetics may reduce the antihypertensive effects produced by angiotensin II receptor antagonists.
Acetaminophen; Dichloralphenazone; Isometheptene: Isometheptene has sympathomimetic properties. Patients taking antihypertensi |
